Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antipsychotic Agents"" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 51163
Tytuł:
Sex-Specific Effects of Long-Term Antipsychotic Drug Treatment on Adipocyte Tissue and the Crosstalk to Liver and Brain in Rats.
Autorzy:
Fehsel K; Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Bergische Landstraße 2, 40629 Düsseldorf, Germany.
Bouvier ML; Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Bergische Landstraße 2, 40629 Düsseldorf, Germany.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 11; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 11.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents*/pharmacology
Antipsychotic Agents*/metabolism
Clozapine*/pharmacology
Rats ; Male ; Female ; Animals ; Haloperidol/pharmacology ; Hepcidins/metabolism ; Rats, Sprague-Dawley ; Adipocytes/metabolism ; Adipose Tissue/metabolism ; Liver/metabolism ; Triglycerides/metabolism ; Glucose/metabolism ; Fatty Acids, Nonesterified/metabolism ; Brain/metabolism ; Perilipins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports.
Autorzy:
Osman AHM; Faculty of Medicine, University of Khartoum, PO Box 201, Khartoum, Sudan. .
Wilkinson J; Caludon Centre, Clifford Bridge Road, Coventry, CV2 2TE, UK.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2024 Apr 18; Vol. 18 (1), pp. 190. Date of Electronic Publication: 2024 Apr 18.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Neuroleptic Malignant Syndrome*/diagnosis
Neuroleptic Malignant Syndrome*/drug therapy
Neuroleptic Malignant Syndrome*/etiology
Antipsychotic Agents*/therapeutic use
Psychotic Disorders*/drug therapy
Adult ; Humans ; Male ; Aripiprazole ; Creatine Kinase
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers.
Autorzy:
Basu A; Department of Psychiatry, All India Institute of Medical Sciences, Kalyani, India.
Dutta AK; Department of Biochemistry, All India Institute of Medical Sciences, Kalyani, India.
Bagepally BS; Indian Council of Medical Research, National Institute of Epidemiology, Chennai, India.
Das S; Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India.; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Cherian JJ; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.; Indian Council of Medical Research, New Delhi, India.
Roy S; Indian Council of Medical Research, New Delhi, India.
Maurya PK; Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India.
Saha I; Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India.
Sukumaran D; Department of Pharmacology, All India Institute of Medical Sciences, Kalyani, India.
Rina K; Department of Psychiatry, All India Institute of Medical Sciences, Kalyani, India.
Mandal S; Department of Psychiatry, All India Institute of Medical Sciences, Kalyani, India.
Sarkar S; Department of Psychiatry, All India Institute of Medical Sciences, Kalyani, India.
Kalita M; Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India.
Bhowmik K; Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India.
Saha A; Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India.
Chakrabarti A; Indian Council of Medical Research, Centre for Ageing and Mental Health, Kolkata, India.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Apr 10; Vol. 19 (4), pp. e0300511. Date of Electronic Publication: 2024 Apr 10 (Print Publication: 2024).
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Schizophrenia*/chemically induced
Antipsychotic Agents*/therapeutic use
Adult ; Humans ; Cost-Benefit Analysis ; Pharmacogenetics ; India ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia.
Autorzy:
He J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Li J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Affiliated Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wei Y; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
He Z; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; School of Mental Health, Wenzhou Medical University, Wenzhou, China.
Liu J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Xiangya Nursing School of Central South University, Changsha, China.
Yuan N; Hunan Provincial Brain Hospital (The second people's Hospital of Hunan Province), Changsha, China.
Zhou R; The Ninth Hospital of Changsha, Changsha, China.
He X; The Ninth Hospital of Changsha, Changsha, China.
Ren H; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Shandong Provincial Hospital, Shandong University, Jinan, China.
Gu L; RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.; Research Center for Advanced Science and Technology (RCAST), University of Tokyo, Tokyo, Japan.
Liao Y; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Chen X; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China. .
Tang J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. .; Hunan Provincial Brain Hospital (The second people's Hospital of Hunan Province), Changsha, China. .; Zigong Mental Health Center, Zigong, China. .
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Apr 02; Vol. 24 (1), pp. 248. Date of Electronic Publication: 2024 Apr 02.
Typ publikacji:
Journal Article
MeSH Terms:
Clozapine*/adverse effects
Schizophrenia*/drug therapy
Schizophrenia*/diagnosis
Antipsychotic Agents*/adverse effects
Humans ; Schizophrenia, Treatment-Resistant ; Receptors, Glutamate/therapeutic use ; Glutamic Acid
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacological Interventions of Atypical Antipsychotics Induced Weight Gain in the Pediatric Population: A Systemic Review of Current Evidence.
Autorzy:
Al Jumaili W; Texas Tech University Health Science Center at Permian Basin, Midland, TX, USA. Wisam_.
Muzwagi A; Texas Tech University Health Science Center at Permian Basin, Midland, TX, USA.
Shah K; Griffin Memorial Hospital-Oklahoma State University, Tulsa, OK, USA.
Trivedi C; Texas Tech University Health Science Center at Permian Basin, Midland, TX, USA.
Durga P; Texas Tech University Health Science Center at Permian Basin, Midland, TX, USA.
Mansuri Z; Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Jain S; Regional Chair of Psychiatry Department, Texas Tech University Health Science Center at Permian Basin, Midland, TX, USA.
Al Jumaili Y; Midland College, Midland, TX, USA.
Pokaż więcej
Źródło:
Child psychiatry and human development [Child Psychiatry Hum Dev] 2024 Apr; Vol. 55 (2), pp. 479-487. Date of Electronic Publication: 2022 Sep 06.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Antipsychotic Agents*/adverse effects
Melatonin*
Metformin*/therapeutic use
Child ; Humans ; Adolescent ; Topiramate ; Betahistine ; Weight Gain ; Amantadine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia- a case series.
Autorzy:
Mølgaard SN; Mental Health Center Glostrup, Copenhagen University Hospital, Unit for complicated schizophrenia, Glostrup, Denmark. .
Nielsen MØ; Mental Health Center Glostrup, Copenhagen University Hospital, Unit for complicated schizophrenia, Glostrup, Denmark.
Roed K; Mental Health Centre Glostrup, Copenhagen University Hospital- Mental Health Services CPH, Centre for Applied Research in Mental Health Care, Glostrup, Denmark.
Nielsen J; Mental Health Center Glostrup, Copenhagen University Hospital, Unit for complicated schizophrenia, Glostrup, Denmark.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Mar 29; Vol. 24 (1), pp. 240. Date of Electronic Publication: 2024 Mar 29.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Schizophrenia*/drug therapy
Schizophrenia*/chemically induced
Humans ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A case report of an atypical severe case of skin picking disorder managed by a multidisciplinary team.
Autorzy:
LeBlanc MA; Department of Psychiatry, Dalhousie University, Abbie J. Lane Building, 6509-5909 Veteran's Memorial Lane, Halifax, NS, B3H 2E2, Canada. .; Nova Scotia Health, Halifax, NS, Canada. .
Hudec MA; Department of Psychiatry, Dalhousie University, Abbie J. Lane Building, 6509-5909 Veteran's Memorial Lane, Halifax, NS, B3H 2E2, Canada.; Nova Scotia Health, Halifax, NS, Canada.
Weise L; Nova Scotia Health, Halifax, NS, Canada.; Division of Neurosurgery, Dalhousie University, Halifax, NS, Canada.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Mar 28; Vol. 24 (1), pp. 238. Date of Electronic Publication: 2024 Mar 28.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antipsychotic Agents*
Self-Injurious Behavior*/diagnosis
Self-Injurious Behavior*/therapy
Self-Injurious Behavior*/complications
Male ; Humans ; Adult ; Excoriation Disorder ; Comorbidity ; Treatment Outcome ; Patient Care Team
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evidence-based Medication knowledge Brokers in Residential Aged CarE (EMBRACE): protocol for a helix-counterbalanced randomised controlled trial.
Autorzy:
Bell JS; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville Campus, Parkville, VIC, 3052, Australia. .
La Caze A; School of Pharmacy, The University of Queensland, Dutton Park, QLD, Australia.
Steeper M; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville Campus, Parkville, VIC, 3052, Australia.
Haines TP; Faculty of Medicine Nursing and Health Sciences, School of Primary and Allied Health Care, Monash University, Clayton, VIC, Australia.; National Centre for Healthy Ageing, Frankston, VIC, Australia.
Hilmer SN; Kolling Institute, Faculty of Medicine and Health, The University of Sydney and Northern Sydney Local Health District, St Leonards, NSW, Australia.; New South Wales Therapeutic Advisory Group, Sydney, NSW, Australia.
Troeung L; Brightwater Research Centre, Brightwater Care Group, Inglewood, WA, Australia.
Quirke L; Dementia Australia, Canberra, Australia.
Wesson J; Ageing and Health Research Unit, Discipline of Occupational Therapy, Faculty of Medicine and Health, Sydney School of Health Sciences, University of Sydney, Camperdown, NSW, Australia.
Pond CD; Wicking Dementia Research and Teaching Centre, University of Tasmania, Hobart, TAS, Australia.
Buys L; Faculty of Health Sciences, Australian Catholic University, Brisbane, QLD, Australia.
Ghahreman-Falconer N; School of Pharmacy, The University of Queensland, Dutton Park, QLD, Australia.; Pharmacy Department, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Lawless MT; Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Bedford Park, Adelaide, South Australia, Australia.
Shrestha S; School of Pharmacy, The University of Queensland, Dutton Park, QLD, Australia.
Martini A; Brightwater Research Centre, Brightwater Care Group, Inglewood, WA, Australia.
Ochieng N; Lifeview Corporate Lifeview Pty Ltd., Carnegie, VIC, Australia.
Glamorgan F; Montefiore, Randwick, NSW, Australia.
Lagasca C; Anglicare Southern Queensland, Fortitude Valley, QLD, Australia.
Walton R; Brightwater Research Centre, Brightwater Care Group, Inglewood, WA, Australia.
Cenin D; Brightwater Research Centre, Brightwater Care Group, Inglewood, WA, Australia.
Kitson A; Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Bedford Park, Adelaide, South Australia, Australia.
Jung M; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville Campus, Parkville, VIC, 3052, Australia.
Bennett A; New South Wales Therapeutic Advisory Group, Sydney, NSW, Australia.
Cross AJ; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville Campus, Parkville, VIC, 3052, Australia. .
Pokaż więcej
Źródło:
Implementation science : IS [Implement Sci] 2024 Mar 04; Vol. 19 (1), pp. 24. Date of Electronic Publication: 2024 Mar 04.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Activities of Daily Living*
Antipsychotic Agents*
Humans ; Aged ; Quality of Life ; Benzodiazepines ; Antidepressive Agents ; Victoria ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Autorzy:
Bhardwaj AK; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia. .; Drug and Alcohol Services, South East Sydney Local Health District, Sydney, NSW, Australia. .
Mills L; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.; Drug and Alcohol Services, South East Sydney Local Health District, Sydney, NSW, Australia.
Doyle M; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.
Sahid A; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.; Drug and Alcohol Services, South East Sydney Local Health District, Sydney, NSW, Australia.
Montebello M; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.; Drug and Alcohol Services, North Sydney Local Health District, St Leonards, NSW, Australia.
Monds L; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.; Drug and Alcohol Services, North Sydney Local Health District, St Leonards, NSW, Australia.
Arunogiri S; Centre for Addiction and Mental Health, Turning Point, Victoria, Australia.
Haber P; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.; Drug Health Services, Sydney Local Health District, Sydney, Australia.
Lorenzetti V; Faculty of Health Science, Australian Catholic University, Victoria, Australia.
Lubman DI; Centre for Addiction and Mental Health, Turning Point, Victoria, Australia.
Malouf P; Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
Harrod ME; NSW Users and AIDS Association, Sydney, NSW, Australia.
Dunlop A; Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW, Australia.
Freeman T; Addiction and Mental Health Group, University of Bath, Bath, UK.
Lintzeris N; Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.; Drug and Alcohol Services, South East Sydney Local Health District, Sydney, NSW, Australia.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Mar 04; Vol. 24 (1), pp. 175. Date of Electronic Publication: 2024 Mar 04.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Cannabidiol*/therapeutic use
Anti-Anxiety Agents*
Hallucinogens*
Substance-Related Disorders*
Cannabis*
Antipsychotic Agents*
Marijuana Abuse*
Adult ; Humans ; Quality of Life ; Australia ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom.
Autorzy:
Woodall AA; Department of Primary Care and Mental Health, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.; Powys Teaching Health Board, Bronllys Hospital, Powys, United Kingdom.
Abuzour AS; Unit for Ageing and Stroke Research, School of Medicine, University of Leeds, West Yorkshire, United Kingdom.
Wilson SA; Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
Mair FS; General Practice & Primary Care, School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.
Buchan I; NIHR Mental Health Research for Innovation Centre, University of Liverpool, Liverpool, United Kingdom.
Sheard SB; Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
Atkinson P; Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
Joyce DW; NIHR Mental Health Research for Innovation Centre, University of Liverpool, Liverpool, United Kingdom.
Symon P; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Walker LE; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 01; Vol. 19 (3), pp. e0294974. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents*/therapeutic use
General Practitioners*
Humans ; Administrative Personnel ; United Kingdom/epidemiology ; Primary Health Care ; Delivery of Health Care
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of chronic haloperidol treatment on the expression of fear memory and fear memory extinction in the cued fear-conditioned rats.
Autorzy:
Enomoto K; Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
Shibata K; Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
Muraoka H; Department of Psychiatry, Kitasato University, Sagamihara-shi, Kanagawa, Japan.
Kawano M; Miyakonojo-Shinsei Hospital, Miyazaki, Japan.
Inada K; Department of Psychiatry, Kitasato University, Sagamihara-shi, Kanagawa, Japan.
Ishigooka J; CNS Pharmacological Research Institute, Tokyo, Japan.
Nishimura K; Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
Oshibuchi H; Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 197-205. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Haloperidol*/pharmacology
Antipsychotic Agents*/pharmacology
Humans ; Rats ; Animals ; Fear/psychology ; Conditioning, Classical ; Cues
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder.
Autorzy:
Nakagome K; National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo, Japan.
Tachimori H; Department of Clinical Data Science, Clinical Research & Education Promotion Division, National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo, Japan.
Endo S; Fujimidai Hospital, Hiratsuka-shi, Kanagawa, Japan.
Murakami K; Murakami Iin, Tokyo, Japan.
Azekawa T; Shioiri Mental Clinic, Yokosuka-shi, Kanagawa, Japan.
Hongo S; Ichigaya Himorogi Clinic, Tokyo, Japan.; Nanko Kokorono Clinic, Shirakawa-shi, Fukushima, Japan.
Niidome K; Medical Affairs, Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan.
Kojima Y; Medical Affairs, Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan.
Yamada S; Medical Affairs, Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan.
Oi H; Department of Clinical Data Science, Clinical Research & Education Promotion Division, National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo, Japan.
Sumiyoshi T; Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 187-196. Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Psychotic Disorders*/drug therapy
Quinolones*/therapeutic use
Schizophrenia*/drug therapy
Thiophenes*/therapeutic use
Humans ; Olanzapine/therapeutic use ; Paliperidone Palmitate/therapeutic use ; Risperidone/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.
Autorzy:
Mostafa S; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; MyDNA Life Australia Limited, Victoria, Australia.
Rafizadeh R; BC Mental Health and Substance Use Services, BC Psychosis Program, Lower Mainland Pharmacy Services, Vancouver, British Columbia, Canada.
Polasek TM; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; Certara, Princeton, New Jersey, USA.; Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Bousman CA; Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Departments of Medical Genetics, Psychiatry, Physiology and Pharmacology, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research (CAPKR), School of Health Sciences, University of Manchester, Manchester, UK.; Simcyp Division, Certara UK Limited, Sheffield, UK.
Stowe R; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.; Djavid Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Neurology (Medicine), University of British Columbia, Vancouver, British Columbia, Canada.
Carrion P; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Sheffield LJ; MyDNA Life Australia Limited, Victoria, Australia.
Kirkpatrick CMJ; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 424-436. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Clozapine*/pharmacokinetics
Clozapine*/therapeutic use
Antipsychotic Agents*/pharmacokinetics
Schizophrenia*/drug therapy
Humans ; Fluvoxamine ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review.
Autorzy:
Oguchi Y; Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Miyake N; Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.; Department of Neuropsychiatry, Kawasaki Municipal Tama Hospital, Kawasaki, Kanagawa, Japan.
Ando K; Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 34-41. Date of Electronic Publication: 2024 Jan 06.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Schizophrenia*/drug therapy
COVID-19*
Humans ; Pandemics ; Injections, Intramuscular
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The efficacy of vortioxetine for the delusional disorder of cenesthopathy.
Autorzy:
Sato S; Department of Psychiatry, Ibaraki Clinical Educational and Training Center, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Imai K; Department of Psychiatry, Hitachi Medical Education and Research Center, University of Tsukuba Hospital, Tsukuba, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 272-274. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:
Case Reports
MeSH Terms:
Schizophrenia, Paranoid*/drug therapy
Antipsychotic Agents*/therapeutic use
Humans ; Aged ; Vortioxetine ; Antidepressive Agents/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20-year period: Retrospective cohort study.
Autorzy:
Kawamata Y; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Kikuchi Hospital, Tochigi, Japan.
Sugawara N; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, TMC Shimotsuga, Tochigi, Japan.
Sasaki T; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Asahi Hospital, Tochigi, Japan.
Yokoyama S; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Aoki Hospital, Tochigi, Japan.
Okayasu H; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Fudogaoka Hospital, Saitama, Japan.
Shinozaki M; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Takizawa Hospital, Tochigi, Japan.
Takeuchi Y; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Okamotodai Hospital, Tochigi, Japan.
Sato A; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Muroi Hospital, Tochigi, Japan.
Ishikawa T; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Saitama-Konan Hospital, Saitama, Japan.
Komahashi-Sasaki H; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, Kanuma Hospital, Tochigi, Japan.
Miyazaki K; Department of Neuropsychiatry, Hirosaki-Aiseikai Hospital, Aomori, Japan.
Fukasawa T; Department of Psychiatry, Seinan Hospital, Aomori, Japan.
Furukori H; Department of Neuropsychiatry, Kuroichi-Akebono Hospital, Aomori, Japan.
Yasui-Furukori N; Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.; Department of Psychiatry, TMC Shimotsuga, Tochigi, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 60-66. Date of Electronic Publication: 2023 Sep 12.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/drug therapy
Antipsychotic Agents*/adverse effects
Dibenzothiepins*
Methotrimeprazine/*analogs & derivatives
Humans ; Female ; Laxatives/adverse effects ; Olanzapine/therapeutic use ; Retrospective Studies ; Quetiapine Fumarate/therapeutic use ; Constipation/chemically induced ; Constipation/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.
Autorzy:
Saga Y; Medical Affairs Division, Janssen Pharmaceutical K.K, Tokyo, Japan.
Chiang CL; Medical Affairs Division, Janssen Pharmaceutical K.K, Tokyo, Japan.
Wakamatsu A; Medical Affairs Division, Janssen Pharmaceutical K.K, Tokyo, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 221-226. Date of Electronic Publication: 2023 Oct 26.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents*/adverse effects
Tardive Dyskinesia*/chemically induced
Tardive Dyskinesia*/drug therapy
Tardive Dyskinesia*/epidemiology
Schizophrenia*/drug therapy
Drug-Related Side Effects and Adverse Reactions*/drug therapy
Humans ; Japan
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data.
Autorzy:
Takekita Y; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Hiraoka S; Medical Affairs Department, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
Iwama Y; Regulatory & Datascience Department, Pharmaceutical Research & Development Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
Matsui D; Safety Vigilance & Management Department, Reliability & Quality Assurance Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
Aoki N; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.; School of Psychiatry, University of New South Wales, Randwick, New South Wales, Australia.; Black Dog Institute, Randwick, New South Wales, Australia.
Ogata H; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Funatsuki T; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Shimizu T; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Murase Y; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Koshikawa Y; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Kato M; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Kinoshita T; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 234-239. Date of Electronic Publication: 2023 Nov 05.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Schizophrenia*/drug therapy
Antipsychotic Agents*/adverse effects
Dibenzocycloheptenes*
Humans ; Treatment Outcome ; Heterocyclic Compounds, 4 or More Rings/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Reducing the use of psychotropics in a convalescent rehabilitation ward.
Autorzy:
Uematsu T; Department of Pharmacy, Kawasaki Kokoro Hospital, Kawasaki, Japan.
Tomita T; Department of Pharmaceutical Sciences, School of Pharmacy, International University of Health and Welfare, Otawara, Japan.; Department of Pharmacy, International University of Health and Welfare Mita Hospital, Minato-ku, Japan.
Obara R; Department of Pharmacy, Kawasaki Kokoro Hospital, Kawasaki, Japan.
Gonai T; Department of Pharmacy, Kawasaki Kokoro Hospital, Kawasaki, Japan.
Hattori K; Department of Rehabilitation, Tohoku University Hospital, Sendai, Japan.; Department of Rehabilitation, Osaki Citizen Hospital, Osaki, Japan.
Aonuma T; Department of Rehabilitation, Kawasaki Kokoro Hospital, Kawasaki, Japan.
Usui K; Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Tanifuji H; Department of Pharmacy, Kodama Hospital, Ishinomaki, Japan.
Ishizawa F; Department of Pharmacy, Kawasaki Kokoro Hospital, Kawasaki, Japan.
Ishii H; Geriatric Psychiatry, Kawasaki Kokoro Hospital, Kawasaki, Japan.
Suzuki E; Division of Psychiatry, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 227-233. Date of Electronic Publication: 2023 Oct 26.
Typ publikacji:
Journal Article
MeSH Terms:
Psychotropic Drugs*
Antipsychotic Agents*
Humans ; Antidepressive Agents ; Hospitals ; Patient Discharge
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings.
Autorzy:
Casetta C; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. .; South London and Maudsley NHS Foundation Trust, London, UK. .
Santosh P; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Bayley R; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Bisson J; Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Byford S; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Dixon C; Wonford House Hospital, Devon Partnership NHS Trust, Exeter, UK.
Drake RJ; Division of Psychology & Mental Health, University of Manchester, Manchester, UK.; Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
Elvins R; Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Emsley R; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Fung N; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Hayes D; South London and Maudsley NHS Foundation Trust, London, UK.
Howes O; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
James A; Department of Psychiatry, University of Oxford, Oxford, UK.
James K; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Jones R; Birmingham and Solihull Mental Health Foundation Trust, Birmingham, UK.
Killaspy H; Division of Psychiatry, University College London, London, UK.
Lennox B; Department of Psychiatry, University of Oxford, Oxford, UK.
Marchant L; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
McGuire P; Department of Psychiatry, University of Oxford, Oxford, UK.
Oloyede E; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Rogdaki M; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Upthegrove R; Institute for Mental Health, University of Birmingham, Birmingham, UK.; Birmingham Early Intervention Service, Birmingham Womens and Childrens NHS Foundation Trust, Birmingham, UK.
Walters J; Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Egerton A; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
MacCabe JH; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Feb 14; Vol. 24 (1), pp. 122. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antipsychotic Agents*/adverse effects
Clozapine*/adverse effects
Schizophrenia*/therapy
Psychotic Disorders*/drug therapy
Child ; Humans ; Adolescent ; Aged ; Adult ; Young Adult ; Schizophrenia, Treatment-Resistant ; Quality of Life ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 51163

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies